Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Joel F Wallace"'
Autor:
David Cella, Robert J Motzer, Cristina Suarez, Steven I Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel F Wallace, Burcin Simsek, Joshua Zhang, Cristina Ivanescu, Andrea B Apolo, Toni K Choueiri
Publikováno v:
Lancet Oncol
In the CheckMate 9ER trial, patients with advanced renal cell carcinoma who received first-line nivolumab plus cabozantinib had significantly better progression-free survival compared with those given sunitinib. In this study, we aimed to describe th
Autor:
David Cella, Kathleen J. Yost, Jing Yi, Herbert Hurwitz, Joel F. Wallace, Fairooz F. Kabbinavar, Eric Holmgren
Publikováno v:
The Oncologist. 13:1021-1029
Purpose. To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of be
Autor:
Kevin Knight, Jay K Udani, Karen Oda, Jeffrey T. Borenstein, Chiun Fang Chiou, James Trussell, Joel F. Wallace, Eileen Reyes
Publikováno v:
Contraception. 68:3-10
Objective To examine from the health care services payer perspective the economic consequences of contraceptives available to women in the United States. Methods A Markov model was constructed to compare effectiveness and costs among nine contracepti
Autor:
Lee S. Schwartzberg, Robert J. Nordyke, Bin Yao, Joel F. Wallace, Chiun Fang Chiou, Chih Hung Chang
Publikováno v:
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, Vol 4, Iss 1, p 28 (2006)
Health and Quality of Life Outcomes, Vol 4, Iss 1, p 28 (2006)
Background Treating anemia associated with chemotherapy and many cancers is often necessary. However, patient satisfaction with anemia treatment is limited by the lack of validated instruments. We developed and validated a new treatment-specific pati
Autor:
Greg Rossi, Frank M. Senecal, Joel F. Wallace, Dianne Tomita, Lorrin Yee, Lee S. Schwartzberg, Veena Charu
Publikováno v:
The oncologist. 9(6)
An important clinical question is the relative efficacy of the most common dosages of darbepoetin alfa (Aranesp®; Amgen Inc.; Thousand Oaks, CA) 200 μg every 2 weeks (Q2W) and epoetin alfa (Procrit®; Ortho Biotech Products, LP; Raritan, NJ) 40,000
Publikováno v:
The oncologist. 9(4)
Primary Purpose. The objective of this retrospective observational cohort study was to compare the effectiveness of darbepoetin alfa with that of epoetin alfa in patients with chemotherapy-induced anemia using data from noncontemporaneous chart audit
Autor:
Joel W. Hay, Peter J. Neumann, Bernard S. Bloom, Joel F. Wallace, Emmett B. Keeler, Hsing-Ting Yu, Sean D. Sullivan, Joshua J. Ofman, James M. Henning, Chiun-Fang Chiou
Publikováno v:
Medical care. 41(1)
To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies.A committee comprising [corrected] of health economists selected a set of criteria for the instrument from an item pool. Data collected with a conj
Autor:
Joel F. Wallace, Andriana A. Hohlbauch, Margaret S. Richards, Chiun-Fang Chiou, Joshua J. Ofman, James M. Henning, Nicole S. Herzog, Lior S. Lewensztain, Scott Weingarten
BACKGROUND: Because there is increasing concern that economic data are not used in the clinical guideline development process, our objective was to evaluate the extent to which economic analyses are incorporated in guideline development. METHODS: We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6903f5339c6ec36d4135d3db411cf2e
https://europepmc.org/articles/PMC1495022/
https://europepmc.org/articles/PMC1495022/
Publikováno v:
Pharmacotherapy. 20(8)
We conducted a cost-effectiveness analysis to compare costs and clinical outcomes of sevelamer versus calcium carbonate plus atorvastatin for treatment of dyslipidemia in patients with chronic renal insufficiency. The model was from the third-party p
Publikováno v:
Blood. 104:4708-4708
Patients with MDS often receive erythropoietic therapy for the treatment of anemia resulting from the disease. This retrospective chart review examined the impact of switching patients from their current dosing regimens of epoetin alfa (Procrit®) to